Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25928766 | 0.96 | ALOX5 (0.34) | ALOX5LIMK1PRKDCALDH1A1MAPT | |
| SCHEMBL25928668 | 0.96 | ALOX5 (0.34) | ALOX5LIMK1PRKDCALDH1A1MAPT | |
| SCHEMBL25928683 | 0.95 | LIMK1 (0.32) | ALOX5LIMK1ALDH1A1ADORA2AADORA1 | |
| SCHEMBL25928611 | 0.94 | ALOX5 (0.40) | ALOX5LIMK1PRKDC | |
| SCHEMBL25928901 | 0.94 | LIMK1 (0.32) | ALOX5LIMK1 | |
| SCHEMBL25928699 | 0.94 | BRDT (0.31) | ALOX5ALDH1A1NTSR1ADORA2AADORA1 | |
| SCHEMBL25730124 | 0.93 | ALOX5 (0.41) | ALOX5LIMK1PRKDC | |
| SCHEMBL25730619 | 0.93 | ALOX5 (0.37) | ALOX5LIMK1PRKDC | |
| SCHEMBL25928931 | 0.93 | LIMK1 (0.32) | ALOX5LIMK1ALDH1A1ADORA2AADORA1 | |
| SCHEMBL25928586 | 0.92 | ALOX5 (0.41) | ALOX5LIMK1PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230247902-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE | LT MATERIALS CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230247902-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE | LT MATERIALS CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230247902-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE | CRY1, PPOX, ORC3 | ALOX5 959/4885LIMK1 226/4885PRKDC 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.